Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.
Menu

Researcher Publications

Yong Lin, PhD

Selected Publications

Methodology:

  1. Lin, Y., Shih, W.J., Lu, S. (2019) "Two-stage enrichment clinical trial design with adjustment for misclassification in predictive biomarkers". Statistics in Medicine. 38:5445-5469. https://pubmed.ncbi.nlm.nih.gov/31621944/
  2. Fang, F., Lin, Y., Shih, W.J., Lu, S., Zhu, G. (2018) "Evaluation of performance of adaptive designs based on treatment effect intervals", International Journal of Statistics and Probability. 7(6):81-93. http://www.ccsenet.org/journal/index.php/ijsp/article/view/0/36892
  3. Shih, W., Lin, Y. (2018) "Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers", Statistics in medicine. 37:687 -709. http://www.ncbi.nlm.nih.gov/pubmed/?term=29205435&report=abstract
  4. Wang, P., Lu, S., Lin, Y., Shih, W.J., Lan, K. (2017) "Two-stage winner designs for non-inferiority trials with pre-specified non-inferiority margin", Journal of Statistical Panning and Inference.183:44-61. https://www.sciencedirect.com/science/article/pii/S0378375816301239
  5. Shih, W., Lin, Y. (2017) "On study designs and hypotheses for clinical trials with predictive biomarkers", Contemporary clinical trials. 62:140-145. http://www.ncbi.nlm.nih.gov/pubmed/?term=28838813&report=abstract
  6. Fang, F, Lin, Y, Shih, W.J., Li, Y., Yang, J., Zhang, X. (2014). "Methods of designing two-stage winner trials with survival outcomes". Statistics in Medicine. 2014 Apr 30;33(9):1539-63. https://pubmed.ncbi.nlm.nih.gov/24347247/.
  7. Wu, Y., Lin, Y., Lu, S., Li, C.S., Shih, W.J. (2014) "Extension of a Cox proportional hazards cure model when cure information is partially known". Biostatistics. 15(3):540-54. https://pubmed.ncbi.nlm.nih.gov/24511081/
  8. Liu J, Lin Y, Shih WJ. On Simon's two-stage design for single-arm phase IIA cancer clinical trials under beta-binomial distribution. Statistics in Medicine. 2010 May 10;29(10):1084-95. PubMed PMID: 20077506.
  9. Liao JG, Wu Y, Lin Y. Improving Sheather and Johes’ bandwidth selector for difficult densities in kernel density estimation. Journal of nonparametric statistics. 2010; 22(1):105-114.
  10. Chu P, Lin Y, Shih WJ. Unifying CRM and EWOC Designs for Phase I Cancer Clinical Trials. Journal of statistical planning and inference. 2009; 139:1146-1163.
  11. Shih WJ, Lin Y. Traditional and modified algorithm-based designs for phase I cancer clinical trials. In Statistical Methods for Dose-Finding Experiments edited by S. Chevret, John Wiley & Sons, Ltd, 61-90, 2006.
  12. Liao JG, Lin Y, Selvanayagam ZE, Shih WJ. A mixture model for estimating the local false discovery rate in DNA microarray analysis. Bioinformatics. 2004 Nov 1;20(16):2694-701. PubMed PMID: 15145810.
  13. Shih WJ, Ohman-Strickland PA, Lin Y. Analysis of pilot and early phase studies with small sample sizes. Statistics in Medicine. 2004 Jun 30;23(12):1827-42. PubMed PMID: 15195318.
  14. Lu SE, Lin Y, Shih WC. Analyzing excessive no changes in clinical trials with clustered data. Biometrics. 2004 Mar;60(1):257-67. PubMed PMID: 15032797.
  15. Lin Y, Shih WJ. Adaptive two-stage designs for single-arm phase IIA cancer clinical trials. Biometrics. 2004 Jun;60(2):482-90. PubMed PMID: 15180674.
  16. Shih WJ, Ouyang P, Quan H, Lin Y, Michiels B, Bijnens L. Controlling type I error rate for fast track drug development programmes. Statistics in Medicine. 2003 Mar 15;22(5):665-75. PubMed PMID: 12587098.
  17. Lin Y, Lindsay BG. Projections on cones, Chi-bar squared distributions, and Weyl's formula. Statistics and Probability Letters. 1997; 32:367-376.
  18. Lin Y, Shih WJ. Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics. 2001 Jun;2(2):203-15. PubMed PMID: 12933550.

Collaborative:

  1. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao SL. Outcomes of localized prostate cancer following conservative management. JAMA. 2009 Sep 16;302(11):1202-9. PubMed PMID: 19755699; NIHMSID: NIHMS172636; PubMed Central PMCID: PMC2822438.
  2. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008 Jul 9;300(2):173-81. PubMed PMID: 18612114; NIHMSID: NIHMS92658; PubMed Central PMCID: PMC2645653
  3. Lehrer PM, Vaschillo E, Vaschillo B, Lu SE, Eckberg DL, Edelberg R, Shih WJ, Lin Y, Kuusela TA, Tahvanainen KU, Hamer RM. Heart rate variability biofeedback increases baroreflex gain and peak expiratory flow. Psychosom Med. 2003 Sep-Oct;65(5):796-805. PubMed PMID: 14508023.
  4. Bandera EV, Chandran U, Buckley B, Lin Y, Isukapalli S, Marshall I, King M, Zarbl H. Urinary mycoestrogens, body size and breast development in New Jersey girls. Sci Total Environ. 2011 Nov 15;409(24):5221-7. PubMed PMID: 21975003; NIHMSID: NIHMS327791; PubMed Central PMCID: PMC3312601.
  5. Jabbour SK, Berman AT, Decker RH, Lin Y, Feigenberg SJ, Gettinger SN, Aggarwal C, Langer CJ, Simone II CB, Bradley JD, Aisner J, Malhotra J. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncology. 2020 Feb 20;e196731. doi: 10.1001/jamaoncol.2019.6731
  6. Shah MM, Rhee K, NeMoyer RE, Lin Y, Jabbour S, Kooby DA, Maithel SK, Carpizo DR. Conditional Survival Analysis of Hepatocellular Carcinoma. Journal of Surgical Oncology, 2020; 122:684-690.
  7. Mehnert JM, Tan AR, Moss R, Poplin E, Stein MN, Sovak M, Levinson K, Lin H, Kane M, Gounder M, Lin Y, Shih WJ, White E, Rubin EH, Karantza V. Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach. Mol Cancer Ther. 2011 Aug;10(8):1509-19. PubMed PMID: 21680752; NIHMSID: NIHMS305287; PubMed Central PMCID: PMC3155243
  8. Makarem N, Lin Y, Bandera EV, Jacques PF, Parekh N. Concordance with World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) guidelines for cancer prevention and obesity-related cancer risk in the Framingham Offspring cohort (1991-2008). Cancer Causes Control. 2015 Feb;26(2):277-86. PubMed PMID: 25559553.
  9. Parekh N, Lin Y, Craft LL, Vadiveloo M, Lu-Yao GL. Longitudinal associations of leisure-time physical activity and cancer mortality in the Third National Health and Nutrition Examination Survey (1986-2006). J Obes. 2012;2012:518358. PubMed PMID: 22675612; PubMed Central PMCID: PMC3361252.
  10. Llanos AAM, Lin Y, Chen W, Yao S, Norin J, Chekmareva MA, Omene C, Cong L, Omilian AR, Khoury T, Hong CC, Ganesan S, Foran DJ, Higgins M, Ambrosone CB, Bandera EV, Demissie K. Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype. Breast Cancer Research, 2020; 22:18; https://doi.org/10.1186/s13058-020-1256-3.
  11. Ju J, Hong J, Zhou JN, Pan Z, Bose M, Liao J, Yang GY, Liu YY, Hou Z, Lin Y, Ma J, Shih WJ, Carothers AM, Yang CS. Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res. 2005 Nov 15;65(22):10623-31. PubMed PMID: 16288056.
  12. Lu YP, Lou YR, Bernard JJ, Peng QY, Li T, Lin Y, Shih WJ, Nghiem P, Shapses S, Wagner GC, Conney AH. Surgical removal of the parametrial fat pads stimulates apoptosis and inhibits UVB-induced carcinogenesis in mice fed a high-fat diet. Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9065-70. PubMed PMID: 22615388; PubMed Central PMCID: PMC3384184
  13. Smolarek AK, So JY, Burgess B, Kong AN, Reuhl K, Lin Y, Shih WJ, Li G, Lee MJ, Chen YK, Yang CS, Suh N. Dietary administration of δ- and γ-tocopherol inhibits tumorigenesis in the animal model of estrogen receptor-positive, but not HER-2 breast cancer. Cancer Prev Res (Phila). 2012 Nov;5(11):1310-20. PubMed PMID: 22964476; NIHMSID: NIHMS405350;
  14. So JY, Wahler JE, Yoon T, Smolarek AK, Lin Y, Shih WJ, Maehr H, Uskokovic M, Liby KT, Sporn MB, Suh N. Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression. Cancer Prev Res (Phila). 2013 Sep;6(9):959-70. PubMed PMID: 23856074; NIHMSID: NIHMS507205;
  15. Chin KV, Seifer DB, Feng B, Lin Y, Shih WC. DNA microarray analysis of the expression profiles of luteinized granulosa cells as a function of ovarian reserve. Fertil Steril. 2002 Jun;77(6):1214-8. PubMed PMID: 12057731.
  16. Gao H, Ouyang X, Banach-Petrosky W, Borowsky AD, Lin Y, Kim M, Lee H, Shih WJ, Cardiff RD, Shen MM, Abate-Shen C. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17204-9. PubMed PMID: 15569926; PubMed Central PMCID: PMC535400.
  17. Wang HY, Luo M, Tereshchenko IV, Frikker DM, Cui X, Li JY, Hu G, Chu Y, Azaro MA, Lin Y, Shen L, Yang Q, Kambouris ME, Gao R, Shih W, Li H. A genotyping system capable of simultaneously analyzing >1000 single nucleotide polymorphisms in a haploid genome. Genome Res. 2005 Feb;15(2):276-83. PubMed PMID: 15687291; PubMed Central PMCID: PMC546529.
  18. Wang HY, Greenawalt D, Cui X, Tereshchenko IV, Luo M, Yang Q, Azaro MA, Hu G, Chu Y, Li JY, Shen L, Lin Y, Zhang L, Li H. Identification of possible genetic alterations in the breast cancer cell line MCF-7 using high-density SNP genotyping microarray. J Carcinog. 2009;8:6. PubMed PMID: 19439911; PubMed Central PMCID: PMC2687141

Return to member profile